Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTKB NYSE:INTT NASDAQ:LAB NASDAQ:PRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTKBCytek Biosciences$4.38-1.8%$4.29$3.28▼$6.18$575.98M1.17779,193 shs597,781 shsINTTinTEST$11.42-10.4%$16.11$6.63▼$20.00$143.49M1.47220,927 shs221,657 shsLABStandard BioTools$0.87+10.0%$0.91$0.70▼$1.72$310.23M1.422.32 million shs3.92 million shsPREPrenetics Global$18.02-1.3%$19.25$7.18▼$23.63$308.12M0.26254,318 shs77,640 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTKBCytek Biosciences-1.79%-3.52%+0.92%-3.95%+21.67%INTTinTEST-10.43%-21.46%-32.78%-38.90%+59.05%LABStandard BioTools+9.97%+6.78%+16.93%-5.90%-37.13%PREPrenetics Global-1.31%-17.57%-3.01%+7.84%+124.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTKBCytek Biosciences$4.38-1.8%$4.29$3.28▼$6.18$575.98M1.17779,193 shs597,781 shsINTTinTEST$11.42-10.4%$16.11$6.63▼$20.00$143.49M1.47220,927 shs221,657 shsLABStandard BioTools$0.87+10.0%$0.91$0.70▼$1.72$310.23M1.422.32 million shs3.92 million shsPREPrenetics Global$18.02-1.3%$19.25$7.18▼$23.63$308.12M0.26254,318 shs77,640 shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTKBCytek Biosciences-1.79%-3.52%+0.92%-3.95%+21.67%INTTinTEST-10.43%-21.46%-32.78%-38.90%+59.05%LABStandard BioTools+9.97%+6.78%+16.93%-5.90%-37.13%PREPrenetics Global-1.31%-17.57%-3.01%+7.84%+124.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTKBCytek Biosciences 2.33Hold$5.6929.85% UpsideINTTinTEST 2.50Moderate Buy$19.0066.37% UpsideLABStandard BioTools 1.67Reduce$1.3554.48% UpsidePREPrenetics Global 2.60Moderate Buy$34.2590.07% UpsideCurrent Analyst Ratings BreakdownLatest INTT, CTKB, PRE, and LAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026LABStandard BioTools Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)7/17/2026PREPrenetics Global Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026PREPrenetics Global BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $40.006/24/2026CTKBCytek Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/16/2026PREPrenetics Global BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.006/3/2026INTTinTEST Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/27/2026LABStandard BioTools Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/13/2026CTKBCytek Biosciences StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$5.50 ➝ $4.755/12/2026CTKBCytek Biosciences Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$6.00 ➝ $5.505/11/2026LABStandard BioTools Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)5/5/2026INTTinTEST Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTKBCytek Biosciences$201.49M2.81N/AN/A$2.67 per share1.64INTTinTEST$121.07M1.19$1.99 per share5.75$7.92 per share1.44LABStandard BioTools$85.33M4.00N/AN/A$1.10 per share0.79PREPrenetics Global$92.39M3.29N/AN/A$9.27 per share1.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTKBCytek Biosciences-$66.54M-$0.57N/A219.00N/A-36.25%-10.07%-7.56%8/5/2026 (Estimated)INTTinTEST$9.34M$0.0449.6528.55N/A2.33%5.31%3.42%N/ALABStandard BioTools-$74.90M$0.204.37N/AN/A73.46%-8.18%-6.43%8/5/2026 (Estimated)PREPrenetics Global-$37.71M-$4.58N/AN/AN/A-62.45%-20.33%-15.42%8/18/2026 (Estimated)Latest INTT, CTKB, PRE, and LAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2026Q2 2026PREPrenetics Global-$0.48N/AN/AN/A$49.85 millionN/A8/5/2026Q2 2026CTKBCytek Biosciences-$0.02N/AN/AN/A$47.31 millionN/A8/5/2026Q2 2026LABStandard BioTools-$0.01N/AN/AN/A$20.80 millionN/A6/10/2026Q1 2026 PreliminaryPREPrenetics Global-$0.49-$0.56-$0.07-$1.36$36.00 million$35.95 million5/7/2026Q1 2026CTKBCytek Biosciences-$0.08-$0.15-$0.07-$0.15$44.23 million$44.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTKBCytek BiosciencesN/AN/AN/AN/AN/AINTTinTESTN/AN/AN/AN/AN/ALABStandard BioToolsN/AN/AN/AN/AN/APREPrenetics GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTKBCytek BiosciencesN/A4.694.07INTTinTEST0.082.261.38LABStandard BioToolsN/A12.3611.92PREPrenetics GlobalN/A5.154.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTKBCytek Biosciences69.46%INTTinTEST63.18%LABStandard BioTools53.74%PREPrenetics Global25.01%Insider OwnershipCompanyInsider OwnershipCTKBCytek Biosciences10.36%INTTinTEST5.20%LABStandard BioTools26.81%PREPrenetics Global7.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTKBCytek Biosciences500129.14 million115.76 millionOptionableINTTinTEST32012.57 million11.69 millionOptionableLABStandard BioTools620390.37 million285.71 millionOptionablePREPrenetics Global116.87 million15.56 millionNot OptionableINTT, CTKB, PRE, and LAB HeadlinesRecent News About These CompaniesWall Street Zen Downgrades Prenetics Global (NASDAQ:PRE) to SellJuly 25, 2026 | americanbankingnews.comPrenetics Global (NASDAQ:PRE) Lowered to "Sell" Rating by Wall Street ZenJuly 25, 2026 | marketbeat.comPrenetics Global: Path To Profitability On Course With Financing DealJuly 24, 2026 | seekingalpha.comTESLA AND ALPHABET SHARES SLUMP IN PRE-MARKET TRADINGJuly 23, 2026 | youtube.comYSidoti Estimates Prenetics Global's Q3 Earnings (NASDAQ:PRE)July 19, 2026 | americanbankingnews.comPrenetics’ IM8 Secures $1 Billion Non-Dilutive Financing as Revenue Outlook RisesJuly 17, 2026 | theglobeandmail.comPRE Continues to Exceed Expectations and Receive Preferential FinancingJuly 17, 2026 | msn.comPrenetics CEO on securing $1 billion funding to fuel subsidiary IM8's growthJuly 17, 2026 | msn.comQ3 Earnings Forecast for Prenetics Global Issued By SidotiJuly 17, 2026 | marketbeat.comQ1 Earnings Estimate for Prenetics Global Issued By SidotiJuly 16, 2026 | marketbeat.comPrenetics Global (NASDAQ:PRE) Price Target Raised to $40.00July 15, 2026 | marketbeat.comPrenetics’ IM8 Secures $1 Billion Growth Financing from General Catalyst’s Customer Value Fund (CVF)July 14, 2026 | markets.businessinsider.comPrenetics Raises $1 Billion Growth Financing from General Catalyst for IM8 and Lifts 2026 Revenue Guidance to $210 Million-$220 MillionJuly 14, 2026 | quiverquant.comQPrenetics' IM8 Secures $1 Billion Growth Financing from General Catalyst's Customer Value Fund (CVF)July 14, 2026 | globenewswire.comPrenetics Global Limited (NASDAQ:PRE) Given Average Rating of "Moderate Buy" by BrokeragesJuly 12, 2026 | marketbeat.comPrenetics Global Limited (PRE) Receives Bullish Coverage as IM8 Targets Supplement Market GrowthJune 25, 2026 | insidermonkey.comPrenetics Global Limited (PRE) Receives Bullish Coverage as IM8 Targets Supplement Market GrowthJune 25, 2026 | finance.yahoo.comCEO chat with Danny Yeung, co-founder and CEO of Prenetics GlobalJune 23, 2026 | msn.comPrenetics Posts Record 2025 Results as IM8 Hits $120 Million ARR and Drives Strategic RefocusJune 15, 2026 | theglobeandmail.comPrenetics Global Falls on Wider 1Q LossJune 12, 2026 | marketwatch.comPRE continues to post rapid growthJune 10, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Ugliest Stocks in the Market Just Got a Very Expensive Vote of ConfidenceBy Bridget Bennett | July 20, 2026Visa’s Open USD Push Puts Circle’s Stablecoin Moat Under PressureBy Jeffrey Neal Johnson | July 5, 2026Boxabl Disrupts Housing With A Tiny Float IPOBy Jeffrey Neal Johnson | July 22, 2026Lockheed Martin Secures the Ultimate Defense MoatBy Jeffrey Neal Johnson | July 9, 2026These Stocks Could Win as Wall Street Looks Beyond AI SoftwareBy Jeffrey Neal Johnson | July 4, 2026INTT, CTKB, PRE, and LAB Company DescriptionsCytek Biosciences NASDAQ:CTKB$4.38 -0.08 (-1.79%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$4.38 0.00 (0.00%) As of 07/29/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.inTEST NYSE:INTT$11.42 -1.33 (-10.43%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$11.20 -0.22 (-1.93%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.inTEST Corporation provides test and process technology solutions for use in manufacturing and testing in automotive, defense/aerospace, industrial, life sciences, security, and semiconductor markets worldwide. The company operates through three segments: Electronic Test, Environmental Technologies, and Process Technologies. The Electronic Test segment offers in2, Cobal, and LS series manipulators that hold various test heads and enable an operator to reposition a test head for alternate use with various probers or handlers on a test floor; and docking hardware products, which protect the interface contacts and ensure proper repeatable and precise alignment between the test head's interface board and the prober's probing assembly. This segment also provides tester interfaces that offer electrical connections between the tester and the wafer prober or IC handler; scorpion flying probe test systems that designs and manufactures robotics-based electronic test equipment; and BRiZ automated test and programming services. Its products are used in production testing of wafers and specialized packaged ICs in back-end testing by semiconductor manufacturers. The Environmental Technologies segment provides ThermoStream products that are used in the semi market as a stand-alone temperature management tool, or in various electronic test applications; thermal chambers; thermal platforms; Thermonics temperature conditioning products that offer tempered gas or fluid; and ultra-cold storage solutions, including biomedical freezers, refrigerators, and mobile storage solutions. The Process Technologies segment offers EKOHEAT and EASYHEAT induction heating systems; and digital streaming and image capturing solutions. The company markets and sells its products to semiconductor manufacturers, third-party foundries, test and assembly providers, and original equipment manufacturers. inTEST Corporation was incorporated in 1981 and is headquartered in Mount Laurel, New Jersey.Standard BioTools NASDAQ:LAB$0.87 +0.08 (+9.97%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$0.88 +0.00 (+0.13%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.Prenetics Global NASDAQ:PRE$18.02 -0.24 (-1.31%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$18.63 +0.61 (+3.39%) As of 07/29/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Meta’s AI Spending Problem Just Found a BlackRock Solution Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
